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Since its discovery and isolation, exogenous insulin has dramati-
cally changed the outlook for patients with diabetes. However,
even when patients strictly follow an insulin regimen, serious
complications can result as patients experience both hyperglyce-
mic and hypoglycemic states. Several chemically or genetically
modified insulins have been developed that tune the pharmaco-
kinetics of insulin activity for personalized therapy. Here, we
demonstrate a strategy for the chemical modification of insulin
intended to promote both long-lasting and glucose-responsive
activity through the incorporation of an aliphatic domain to fa-
cilitate hydrophobic interactions, as well as a phenylboronic acid
for glucose sensing. These synthetic insulin derivatives enable
rapid reversal of blood glucose in a diabetic mouse model following
glucose challenge, with some derivatives responding to repeated
glucose challenges over a 13-h period. The best-performing insulin
derivative provides glucose control that is superior to native insulin,
with responsiveness to glucose challenge improved over a clinically
used long-acting insulin derivative. Moreover, continuous glucose
monitoring reveals responsiveness matching that of a healthy
pancreas. This synthetic approach to insulin modification could
afford both long-term and glucose-mediated insulin activity,
thereby reducing the number of administrations and improving
the fidelity of glycemic control for insulin therapy. The described
work is to our knowledge the first demonstration of a glucose-
binding modified insulin molecule with glucose-responsive activity
verified in vivo.
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Insulin is a key component in the treatment of both type I andtype II diabetes, diseases that are steadily increasing in prev-
alence (1–3). For insulin-dependent patients, best therapeutic
outcomes are observed when a regimented insulin administration
schedule is followed (4). Some patients respond well to insulin
therapy, and a cohort exists as part of the Joslin Medalist pro-
gram that has survived for 50 or more years with total insulin
dependence (5). However, most insulin-dependent patients suf-
fer from complications that arise from poor adherence to therapy
or from inadequate glycemic control (6). Acute hypoglycemic
episodes can result in coma or death (7). Furthermore, chronic
instability in glucose levels can lead to cardiovascular disease and
nonhealing wounds and is an independent predictor of total, car-
diovascular, and cancer mortality (8). There remains a need to
address the kinetics of insulin therapy to more closely match the
natural dynamics in insulin signaling and blood glucose levels and
to improve the autonomy of insulin therapy.
Extensive efforts have been taken to develop and commer-
cialize insulin variants with tunable pharmacokinetics (9, 10).
These efforts have led to variants with rapid activity and those
with prolonged activity; combinations of various types may be
useful to improve patient-specific glycemic control. Native un-
modified insulin has an onset time of 30–60 min, a peak window
of action from 2 to 3 h, and a duration of action up to 8 h (4). In
comparison, fast-acting variants have been developed, for ex-
ample, by switching the position of the B29 lysine residue and the
B28 proline residue (Insulin lispro) to inhibit dimer formation
and improve uptake (11). Insulin lispro reduces onset time to just
5–15 min, with peak action at 30–60 min and duration of action
up to 5 h (4). Long-acting variants have also been developed, for
example, by covalently attaching a saturated 14-carbon alkyl
segment to the e-amine of B29 lysine (Insulin detemir), enabling
the insulin to bind to and be sequestered by circulating serum
albumin. As a result, Insulin detemir has an onset of action of
1–2 h, with a peak action at 3–9 h and duration lasting up to 24 h
(4). As a component in diabetes management, long-acting insulin
is particularly useful as a daily injection to provide basal insulin
and limit spikes in blood glucose levels throughout the day (12).
Here, we synthesized and developed a class of insulin deriva-
tives that is designed to afford long-lasting and glucose-mediated
activity toward the generation of glucose-responsive chemically
modified insulin. To prepare these insulin derivatives, small
molecules containing both an aliphatic moiety and a phenyl-
boronic acid (PBA) moiety were synthesized for covalent con-
jugation to insulin. The use of an aliphatic domain was inspired
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by the design of long-acting Insulin detemir to afford binding to
serum albumin, or other hydrophobic components in serum, for
prolonged circulation half-life (13, 14). Meanwhile, incorpora-
tion of PBA provides a glucose-sensing element within the con-
jugate, as PBAs are known to bind reversibly to cis-1,2 or cis-1,3
diols such as glucose, which stabilizes a negative charge on the
boronic acid (15). The inclusion of PBA groups within polymers
has been previously used for glucose sensing and insulin delivery
through modulation of electrostatics upon glucose binding to PBA
(16), and PBA has also been evaluated as an element in optical
glucose sensors (17). Here, we demonstrate that derivatizing
insulin with aliphatic PBA conjugates affords long-lasting and
glucose-responsive activity, providing a potentially improved thera-
peutic strategy for diabetes management.
Results
The desired conjugates, containing both an aliphatic domain and
a PBA, were synthesized according to methods outlined in Fig.
1A and Scheme S1. The PBA moieties were coupled to the ali-
phatic domain by direct amidation of either commercially
available PBAs or phenyl bromides followed by a Suzuki cou-
pling reaction. This approach afforded aliphatic groups termi-
nally substituted with four different PBA moieties. The design of
these conjugates included fluoro-, nitro-, and sulfo-containing
PBAs, intended to provide electron-withdrawing character to
lower the pKa of the phenylboronic acid and facilitate the glu-
cose-binding species at physiologic pH (18). Using dicyclohexyl-
carbodiimide (DCC)/N-hydroxysuccinimide (NHS) coupling
under basic conditions, conjugates were attached to insulin
preferentially at the e-amine of the B29 lysine residue (Fig. 1B).
Similar methods have been previously demonstrated to afford
selectivity in functionalizing this primary amine instead of either
the A1 or B1 N-terminal amines of insulin (19, 20). These
methods resulted in four PBA-containing aliphatic insulin deriva-
tives (Fig. 1C), with amido- (Ins-PBA-A), fluoro- (Ins-PBA-F),
nitro- (Ins-PBA-N), or sulfo- (Ins-PBA-S) modified PBA groups.
In addition, control long-acting insulin (Ins-LA-C14) was pre-
pared through myristic acid conjugation, producing modified
insulin with the same structure as the commercially used long-
acting Insulin detemir (13, 14). All modified insulin derivatives
were purified using preparative scale HPLC to afford the puri-
fied product specifically modified at the B29 lysine (Fig. S1).
To determine whether covalent modification had an effect on
secondary structure of insulin, we evaluated all of the modified
derivatives using near-UV circular dichroism (CD) (Fig. S2). All
insulin derivatives were observed to have CD spectra consistent
primarily with α-helical secondary structure. Modified deriva-
tives had a subtle blue-shift in their CD signature, consistent with
previous findings for CD spectra of acylated insulin (21), but
overall the α-helical character of native insulin was maintained.
To ensure there were no deleterious effects of modification on
insulin function, a cell-based insulin receptor activation assay
was performed (Fig. S3). Modification of insulin with aliphatic
PBA conjugates or myristic acid was found to have no significant
effect on insulin activity relative to native unmodified insulin.
A mouse model of insulin-deficient diabetes, prepared using
streptozotocin (STZ) to induce pancreatic β-cell death (22), was
used to evaluate the function of the modified insulin derivatives
developed here. All PBA-modified insulins reduced blood glu-
cose levels to a normoglycemic level, <200 mg/dL for a mouse,
following a single s.c. administration of 5 IU/kg insulin or mass
equivalent of modified insulins (Fig. 2). Four hours following
administration, an i.p. glucose tolerance test (IPGTT) was ad-
ministered. Following a spike in blood glucose, all four PBA-
modified insulin derivatives restored blood glucose to a normo-
gylcemic level, whereas native insulin did not have an effect on
reducing blood glucose. Of note, Ins-PBA-S, Ins-PBA-F, and
Ins-PBA-N derivatives completely reversed blood glucose to
prechallenge levels. After a second IPGTT, performed 7 h fol-
lowing initial insulin administration, Ins-PBA-S, Ins-PBA-F, and
Ins-PBA-N were again able to restore normoglycemic levels. Ins-
PBA-A was not able to restore normoglycemia following the
second challenge. A third IPGTT performed at 10 h following
insulin administration revealed that Ins-PBA-F and Ins-PBA-N
were still able to restore normoglycemia. Ins-PBA-F was espe-
cially potent in reversing blood glucose levels to prechallenge
levels, and thus, this insulin was identified as a promising can-
didate for further evaluation.
To establish the glucose dependence of Ins-PBA-F, we per-
formed dosing studies in both STZ-induced diabetic mice and
Fig. 1. Schematic illustrating the strategy for insulin modification. (A) Generalized scheme to prepare small molecules used in the preparation of Ins-PBA-F,
Ins-PBA-N, and Ins-PBA-A. (B) Final carboxylic acid-containing small molecule is conjugated to the native human insulin protein through the e-amine of the
lysine at the B29 position (yellow). (C) Structures of the four PBA-modified long-acting insulin derivatives used in this work along with the positive control, Ins-
LA-C14, commercially known as insulin detemir. Detailed schematic and methods, including those for synthesis of Ins-PBA-S, can be found in SI Methods.
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healthy mice (Fig. 3). In these studies, our best performing in-
sulin (Ins-PBA-F) was compared with the active ingredient of
a clinically used long-acting insulin formulation (Ins-LA-C14,
Insulin detemir) in insulin-deficient mice to investigate whether
the observed effect was not simply a result of long-lasting ac-
tivity. Doses equivalent to 1, 3, and 5 IU/kg of native insulin were
chosen as a therapeutically relevant dose range. In diabetic mice,
following insulin administration, blood glucose levels for all mice
dropped. At 3 h following dosing with insulin, an IPGTT was
performed. To measure insulin responsiveness, the area under
the curve was calculated for each insulin between 3 and 6 h (Fig.
3D). As shown, at both 1 and 3 IU/kg, Ins-PBA-F was signifi-
cantly (P < 0.05) more responsive to glucose challenge than ei-
ther Ins-LA-C14 or native insulin. At 5 IU/kg, both Ins-PBA-F
and Ins-LA-C14 were significantly (P < 0.05) more responsive
than native insulin, but there were no significant difference be-
tween the responsiveness of these two groups. Dosing studies
were also performed in a healthy normoglycemic mouse. In these
studies, the extent to which insulin elicited hypoglycemia was
quantified using a hypoglycemia index, a measure of the drop
from initial blood glucose reading to the nadir (i.e., lowest ob-
served) value divided by the time over which this drop occurred
(Fig. 3H). A similar metric is used clinically in the evaluation of
diabetic patients (23). For healthy mice dosed at 1 IU/kg, the
hypoglycemia index for Ins-PBA-F was significantly (P < 0.05)
less than that for native insulin, whereas the hypoglycemia index
for Ins-LA-C14 was not less that for native insulin. At 3 and 5
IU/kg, Ins-PBA-F resulted in a significant (P < 0.05) reduction in
the hypoglycemic index compared with both Ins-LA-C14 and
native insulin. Taken together, the results in diabetic and healthy
mice indicate higher activity of Ins-PBA-F in response to glucose
challenge, with a reduced hypoglycemic index when administered
in a normoglycemic state.
To further evaluate the kinetics and responsiveness of PBA-
modified insulin analogs in response to IPGTT, continuous
glucose monitoring was used to provide 5-min resolution for
blood glucose measurements (Fig. S4A). Healthy age-matched
mice were used as a positive control as a comparison for the
responsiveness of a fully functioning pancreas. Following
administration, both insulin derivatives reversed blood glucose
to normoglycemic levels, but the slope of this decrease
was significantly faster for Ins-PBA-F than for Ins-LA-C14
(Fig. S4C). An IPGTT was performed 3 h following insulin
administration, which prompted a comparable rise in blood
glucose levels in all groups. However, when mice were treated
with Ins-PBA-F, a rapid reversal was observed following chal-
lenge that was similar in slope to the response seen for a healthy
mouse with no insulin deficiency (Fig. S4D). In the case of the
long-acting variant, Ins-LA-C14, the response following glucose
challenge was much slower than both the Ins-PBA-F and healthy
control. Although the slopes between different insulins varied
considerably, the slopes for each individual treatment after initial
administration and following IPGTT were similar. To quantify
responsiveness of Ins-PBA-F and Ins-LA-C14 compared with the
healthy control, area under the curve was calculated from the
beginning of IPGTT at 3 h until the 6-h end point of the study.
The responsiveness of Ins-PBA-F was comparable to that for
a healthy animal, whereas the Ins-LA-C14 had a much larger
area and did not return to baseline over the timeframe in-
tegrated (Fig. S4B).
It has been reported that PBAs bind more strongly to fructose
than they do to glucose (24). To examine diol-mediated activa-
tion of Ins-PBA-F, an IP challenge was performed using fructose
instead of glucose. For treatment with Ins-PBA-F, glucose
challenge resulted in a spike and reversal of blood glucose levels
(Fig. S5A), as previously demonstrated in other experiments.
However, when fructose was instead used for challenge, blood
glucose levels were only slightly elevated and quickly returned to
baseline for the duration of the study. When glucose was used to
challenge following Ins-LA-C14 treatment, the behavior was
similar to that seen in previous studies. In contrast, treatment
with Ins-LA-C14 demonstrated a gradual rise in blood glucose
levels following fructose challenge (Fig. S5B), likely due to the
conversion of administered fructose into glucose (25).
We hypothesized that the glucose-responsive activity demon-
strated by these aliphatic PBA conjugates functioned through
glucose-mediate binding to serum proteins, such as serum al-
bumin, as the mechanism for insulin activation. We compared
the binding kinetics of Ins-PBA-F, Ins-LA-C14, and native
insulin to human serum albumin (HSA) using biolayer in-
terferometry (Fig. S6). The mechanism underlying the long-
lasting activity of Ins-LA-C14 (i.e., Insulin detemir) has been
reported to be binding to serum albumin (26). The calculated
binding constant, fitting to a 1:1 binding model, for Ins-PBA-F
to HSA was comparable to that for Ins-LA-C14 (2.81 vs. 2.18 nM,
respectively) in the absence of glucose. In the presence of glu-
cose, the binding constant was not significantly changed (3.65 nM
for Ins-PBA-F and 2.56 nM for Ins-LA-C14). These data indicate
that binding of PBA-modified insulin to HSA is insensitive to the
presence of physiologically relevant glucose concentrations in this
specific assay and though this mechanism may still hold, an alter-
nate glucose-responsive mechanism could also be responsible for
the differential activity observed in vivo.
Discussion
Previous work toward the preparation of self-regulated insulin
therapy has explored, for example, the use of glycosylated insu-
lins in combination with glucose-binding lectins such as Con A
(27–31). This technology has generally comprised a device, capsule,
or pouch containing lectin-bound glycosylated insulin to be re-
leased as circulating glucose levels increase. Here, we developed
a strategy for the covalent modification of insulin intended to
couple an aliphatic domain for long-lasting activity with PBA as
a glucose-sensing element to prepare a soluble, circulating, glu-
cose-sensing modified insulin molecule. Although PBAs have
been fused to insulin previously as a method for preparing glu-
cose-responsive self-assemblies of insulin (19, 20), our report
here illustrates, to our knowledge, the first demonstration of
glucose-responsive activity for a PBA-modified insulin in an
animal model of diabetes. Through screening of different PBA-
containing aliphatic conjugates, Ins-PBA-F was identified as the
Fig. 2. Initial screen of PBA-modified insulin derivatives in an STZ-induced
diabetic mouse model. Insulin derivatives or native insulin were injected at
a dose of 5 IU/kg (173.5 μg/kg) at the beginning of the experiment (0 h), with
a series of IPGTTs performed at 4, 7, and 10 h following insulin administra-
tion. Blood glucose from peripheral tail vein puncture was monitored
throughout the study to follow insulin activity.

















Fig. 3. Dose escalation studies in diabetic (left column) and healthy (right column) mice to evaluate the potency of Ins-PBA-F compared with Ins-LA-C14
and native insulin. Insulins were dosed corresponding to insulin-equivalent doses of 1 IU/kg (34.7 μg/kg, first row), 3 IU/kg (104.1 μg/kg, second row), and
5 IU/kg (173.5 μg/kg, third row) at time 0, and blood glucose was monitored for 6 h. (A–C ) Dosing studies in diabetic mice, with insulin administered s.c. at
time 0 and an IPGTT performed 3 h following insulin administration. (D) The responsiveness of each insulin was calculated based on the area under the
curve from 3 to 6 h, with the baseline set at the 3-h blood glucose reading. (E–G) Dosing studies in healthy mice, with insulin administered s.c. at time 0.
(H) Quantification of hypoglycemia index, which was determined from the difference between the initial and nadir blood glucose readings divided
by the time at which nadir (i.e., lowest observed value) was reached. For D and H, ANOVA with Bonferroni multiple comparisons post hoc test was performed.
★P < 0.05 for Ins-PBA-F compared with both Ins-LA-C14 and native insulin; ▾P < 0.05 for Ins-PBA-F compared with native insulin; •P < 0.05 for Ins-LA-C14
compared with native insulin.
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most promising modification for long-lasting, glucose-responsive
behavior. To analyze glucose-responsive activity, a dosing study
in both diabetic and healthy mice was performed. In diabetic
mice, Ins-PBA-F exhibited significantly higher potency and re-
sponsiveness compared with native insulin or a control of clini-
cally used long-lasting modified insulin (Ins-LA-C14) across
a range of doses. Conversely, in healthy mice with lower basal
blood glucose levels, the hypoglycemia index for Ins-PBA-F was
significantly reduced. Enhanced potency and responsiveness in
a hyperglycemic state coupled with reduced activity in a euglycemic/
hypoglycemic state suggests that Ins-PBA-F has glucose-mediated
potency. Through continuous glucose monitoring, it was also
established that the kinetics of Ins-PBA-F in responding to a glu-
cose challenge were comparable to those for insulin produced
from a healthy pancreas. Glucose-mediated binding to serum al-
bumin could not be confirmed as the mechanism of action for the
glucose-dependent activity of Ins-PBA-F observed here. Though
glucose-responsive binding to hydrophobic domains in proteins
such as serum albumin may still be the underlying mechanism,
another possible mechanism is that PBA-modified insulin binds
reversibly to immobilized diols, such as those on glycoproteins,
glycosylated proteins, proteoglycans, or glycosaminoglycans. We
note that the diabetic state increases the extent of protein glyco-
sylation (32), increasing the number of potential binding sites
available by this mechanism.
Insulin therapy could be improved by greater autonomy, in-
creased fidelity in glycemic control, and reduced hypoglycemia
(33). Even with perfect use, traditional insulin therapy fails
to match the kinetics of normal insulin signaling. Even small
improvements in glycemic control over time have the potential to
reduce the frequency of serious complications, including blind-
ness, cardiovascular disease, stroke, nonhealing wounds, and
cancer (8). Glucose-responsive insulin, with bioactivity that is
regulated by glucose levels in the body, could improve glycemic
control. The safety and toxicity for covalent modification of in-
sulin with aliphatic PBA conjugates remains to be established.
Insulin therapy necessitates repeated administrations over a
lifetime, and risk for both allergic reaction and antibody for-
mation must be minimized before clinical use. Of note, the
clinical incidence of adverse reaction to insulin is less than 1%
(34), and B29-modified variants such as detemir and degludec
have generally demonstrated excellent safety profiles with lim-
ited evidence of antibody formation or allergic reaction (34–37).
In summary, to our knowledge, this is the first demonstration
of glucose-responsive behavior in vivo with a modified insulin
derivative. Covalent modification of insulin with conjugates
containing an aliphatic domain and a PBA afforded long-lasting
insulin with glucose-mediated activity. The lead candidate dem-
onstrated enhanced responsiveness to glucose challenge in di-
abetic mice but a reduction in hypoglycemic index in healthy mice.
It is possible that these modified insulins could interface with in-
sulin pumps, infusion devices, or controlled release materials to
further improve performance.
Methods
Detailed experimental methods can be found in SI Methods. Briefly, small
molecule conjugates were synthesized starting from 12-aminododecanoic
acid and were coupled to insulin using DCC/NHS chemistry under basic
conditions. Ins-LA-C14 was prepared using commercially available myristic
acid. Insulin derivatives were purified by HPLC to afford the species specif-
ically modified at the B29 lysine. Site-specific modification of insulin was
confirmed using tandem MS/MS electrospray ionization (ESI) mass spec-
trometry on DTT/trypsin digests with Mascot proteomic analysis. Circular
dichroism was used to verify secondary structure of insulin derivatives,
whereas a cell-based protein kinase B (AKT) phosphorylation assay was used
to confirm insulin bioactivity. An STZ-induced animal model was used to
evaluate insulin derivatives in vivo. Mice were fasted overnight and then
injected with insulin s.c. at a range of doses. In cases where glucose chal-
lenge was administered, this was done through i.p. injection of a glucose
solution. Studies in healthy mice to assess hypoglycemia were dosed iden-
tically but were not subjected to a glucose challenge. Continuous glucose
monitoring was performed using clinically used s.c. monitoring devices. All
animal studies were conducted through protocols approved by the MIT
animal care and use committee, following all institutional, state, and federal
guidelines for the use of research animals. Binding to human serum albumin
was established using biolayer interferometry, with binding constants
obtained through fitting the complete data to a 1:1 binding model.
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